TY  - JOUR
AU  - Girard, Nicolas
AU  - Minchom, Anna
AU  - Ou, Sai-Hong Ignatius
AU  - Gadgeel, Shirish M
AU  - Trigo, Jose
AU  - Viteri, Santiago
AU  - Bauml, Joshua M
AU  - Londhe, Anil
AU  - Mahadevia, Parthiv
AU  - Bazhenova, Lyudmila
PY  - 2022
DO  - 10.1016/j.cllc.2022.07.007
UR  - http://hdl.handle.net/10668/22105
T2  - Clinical lung cancer
AB  - The activity of immune checkpoint inhibitors (ICIs) in NSCLC harboring EGFR exon 20 insertion mutations (ex20ins) has not been closely examined due to the frequent exclusion of patients with EGFR mutations from large immunotherapy-based NSCLC trials....
LA  - en
PB  - Elsevier
KW  - Immunotherapy
KW  - Mutation
KW  - Real-world data
KW  - Real-world overall survival
KW  - Time to next treatment
KW  - Humans
KW  - Carcinoma, Non-Small-Cell Lung
KW  - ErbB Receptors
KW  - Immune Checkpoint Inhibitors
KW  - Lung Neoplasms
KW  - Mutation
KW  - Retrospective Studies
TI  - Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.
TY  - research article
VL  - 23
ER  -